OakChart

Lyell Immunopharma Inc

LYELHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

16.86+0.11 (0.66%)
2026-11-12 06:29 CET
Market cap
414.51 USD m
Revenue, TTM
0.01 USD m
Net income, TTM
-255.16 USD m
Free cash flow, TTM
-139.97 USD m
EPS diluted, TTM
-11.50
P/E
-
Compare

Price

LYEL against its 20, 50 and 200-day averages
2050200earnings
10.0015.0020.00847K1.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LYELclose 16.8620-day 11.5850-day 10.97200-day 16.4716.8652w low

62.5% under the 52-week high of 45.00 on 22 Dec 2025. 52-week low 7.20 on 14 Oct 2026. Last 15 sessions, 94.6% high to low

Volume 0.90× normal · the line is the 50-bar volume average

Profile

LYEL
52-week range, 26% of the way up
7.2045.00

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

IndexRUT
Employees161
IPOJun 17, 2021
Beta-0.17
ATR, 14d1.37
Rel volume0.90
Short float15.86%
Insider own63.83%
Inst own21.58%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap414.51M
Enterprise Value281.68M
Income-255.16M
Sales0.01M
Book/sh7.84
Cash/sh7.20
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees161
IPOJun 17, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S41451.44
P/B2.15
P/C2.34
P/FCF-
EV/EBITDA-
EV/Sales28168.44
Quick Ratio4.02
Current Ratio4.02
Debt/Eq0.23
LT Debt/Eq0.18
Option/ShortYes / Yes

Earnings

EPS (ttm)-11.50
EPS next Y-6.99
EPS next Q-1.98
EPS this Y56.58%
EPS next Y-0.20%
EPS next 5Y28.54%
EPS past 3/5Y-2.70% 0.99%
Sales past 3/5Y-92.48% -65.85%
EPS Y/Y TTM49.87%
Sales Y/Y TTM-63.41%
EPS Q/Q12.38%
Sales Q/Q-80.00%
EarningsNov 04 AMC
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own63.83%
Insider Trans41.79%
Inst Own21.58%
Inst Trans-0.15%
ROA-74.85%
ROE-97.79%
ROIC-112.39%
Gross Margin-59933.33%
Oper. Margin-
Profit Margin-
SMA2045.56%
SMA5053.66%
SMA2002.38%
Trades-

Technical

Shs Outstand24.58M
Shs Float8.89M
Short Float15.86%
Short Ratio8.28
Short Interest1.41M
52W High45.00 -62.53%
52W Low7.20 134.33%
Volatility13.10% 11.34%
ATR (14)1.37
RSI (14)80.04
Beta-0.17
Rel Volume0.90
Avg Volume170.23K
Volume153,687

Performance

Perf Week9.27%
Perf Month124.50%
Perf Quarter22.71%
Perf Half Y-12.37%
Perf YTD-45.22%
Perf Year-2.26%
Perf 3Y-49.06%
Perf 5Y-92.68%
Perf 10Y-
Recom1.57
Target Price38.29
Prev Close16.75
Price16.86
Change %0.66%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Aug 06, 2026InitiatedSStifelBuy$36+113.5%
Jul 22, 2026InitiatedRB. Riley SecuritiesBuy$44+161.0%
May 01, 2026InitiatedRRobert W. BairdOutperform$49+190.6%
Apr 10, 2026InitiatedNNeedhamBuy$44+161.0%
Mar 09, 2026InitiatedCCitizensMkt Outperform$34+101.7%
Dec 09, 2025UpgradeHH.C. WainwrightNeutral → Buy$45+166.9%
Oct 30, 2024DowngradeBBofA SecuritiesBuy → Underperform$6 → $1-94.1%
Jun 27, 2024DowngradeHH.C. WainwrightBuy → Neutral$6 → $1-94.1%
Aug 28, 2023DowngradeJJP MorganOverweight → Neutral$15 → $5-70.3%
Nov 14, 2022DowngradeMMorgan StanleyOverweight → Equal-Weight$15 → $7-58.5%

Peers

Mkt cap
TickerCompanyMkt cap
ALLOAllogene Therapeutics Inc311.85M
AUTLAutolus Therapeutics plc ADR328.71M
CRBUCaribou Biosciences Inc42.21M
ACETAdicet Bio Inc27.99M
FATEFate Therapeutics Inc195.12M
NKTXNkarta Inc106.12M
LEGNLegend Biotech Corp ADR3.79B
SANASana Biotechnology Inc686.16M
CABACabaletta Bio Inc312.79M
GILDGilead Sciences Inc210.52B

Insider trading

latest 14 of 29
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ARCH Venture Partners IX, LLC10% OwnerNov 04 '26Buy10.772,321,26224,999,9923,747,790Nov 05 05:35 PM
ARCH Venture Fund XIII, L.P.10% OwnerNov 04 '26Buy10.772,321,26224,999,9923,747,790Nov 05 05:34 PM
Aguirre Jarrad MattieuChief Medical OfficerOct 12 '26Sale8.634223,64219,857Oct 13 05:17 PM
Shook DavidChief Medical OfficerSep 10 '26Sale12.705006,35020,423Sep 10 07:37 PM
Seely LynnPresident and CEOAug 21 '26Sale15.549,589149,01363,899Aug 25 04:06 PM
Hill Stephen J.Chief Operating OfficerAug 21 '26Sale15.5498915,36916,816Aug 25 04:05 PM
Lee Gary K.Chief Scientific OfficerAug 21 '26Sale15.541,45722,64216,220Aug 25 04:03 PM
Bulis Veronica SanchezVP, Corporate ControllerAug 10 '26Sale14.346218,90514,799Aug 11 04:21 PM
Lee Gary K.Chief Scientific OfficerAug 10 '26Sale14.341311,87917,677Aug 11 04:20 PM
Hill Stephen J.Chief Operating OfficerAug 10 '26Sale14.34891,27617,805Aug 11 04:18 PM
Seely LynnPresident and CEOAug 10 '26Sale14.343905,59373,488Aug 11 04:07 PM
Innovative Cellular Therapeuti10% OwnerJul 17 '26Sale13.70101372,857,480Jul 20 02:55 PM
Innovative Cellular Therapeuti10% OwnerJul 16 '26Sale13.73101372,857,490Jul 17 09:45 PM
Seely LynnPresident and CEOMay 11 '26Sale18.913887,33773,878Jun 15 06:37 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press) +43.27%
  • Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 (GlobeNewswire)
  • Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission (GlobeNewswire)
  • Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma (GlobeNewswire)
  • Lyell Immunopharma To Participate in November Investor Events (GlobeNewswire)
  • Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference (GlobeNewswire) -5.27%
  • Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer (GlobeNewswire) -5.28%
  • Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press) +5.65%
  • Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 (GlobeNewswire)
  • Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)
  • Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire)
  • Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress (GlobeNewswire)
  • Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion (GlobeNewswire)
  • Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress (GlobeNewswire) -8.28%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-1.908-1.908-2.0000.000.008
2026Q22026-08-12-1.920-1.900-1.9160.000.008
2026Q12026-05-06-1.190-1.312-1.1040.000.006
2025Q42026-03-12-7.130-2.232-6.6220.010.025
2025Q32025-11-12-2.130-2.643-2.1260.020.004
2025Q22025-08-14-2.890-3.520-2.8850.010.003
2025Q12025-05-13-1.860-3.600-3.5370.010.003
2024Q42025-03-12-14.100-3.400-14.4020.010.004
2024Q32024-11-07-3.200-3.900-3.4790.030.004
2024Q22024-08-07-3.600-3.950-3.5870.010.004
2024Q12024-05-06-4.786-4.400-4.7720.000.003
2023Q42024-02-29-4.134-4.600-4.1830.010.005
2023Q32023-11-07-3.850-4.840-4.0470.030.015
2023Q22023-08-08-5.200-5.250-5.1070.030.024
2023Q12023-05-05-3.600-5.150-5.3650.07-0.024
2022Q42023-03-02-0.600--0.67348.39-4

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-30.650-29.436-20.61610.659.41
2022FY-13.200-17.200-14.82384.6849.32
2023FY-18.624-18.320-18.6970.132.07
2024FY-26.249-14.600-26.2350.060.05
2025FY-16.060-10.530-16.0600.040.04
2026FY--6.973--0.01
2027FY--6.986--0.01
2028FY--5.860--45.23
2029FY--4.030--190.79
2030FY--2.907--307.48

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-056100.010.000.04
2026Q4S2026-11-046100.010.000.04
2026Q4S2026-08-275000.000.000.01
2026Q4S2026-08-196000.000.000.01
2026Q4S2026-08-136010.000.000.01
2026Q4S2026-08-116010.000.000.01
2026Q4S2026-07-205010.000.000.01
2026Q4S2026-06-054010.000.000.01
2026Q4S2026-05-074100.010.000.02
2026Q4S2026-04-094010.000.000.01
2026Q4S2026-03-133010.000.000.01
2026Q4S2026-03-061000.010.010.01
2026Q4R2026-11-05210-1.96-2.18-1.73
2026Q4R2026-11-04210-1.96-2.18-1.73

Estimate history

EPS, annual-10.587-16.875-20.616-14.823-18.697-26.235-16.056-11.5047
Period2019202020212022202320242025TTM
EPS, quarterly-3.479-14.402-3.537-2.885-2.126-6.622-1.104-1.916-1.863
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.6577.75610.6584.6830.130.0610.0360.01
Period2019202020212022202320242025TTM
Sales, quarterly0.0340.0110.0070.0080.0150.0060.0020.0040.003
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual12.32912.32912.13712.47812.69814.74421.25124.581
Period2019202020212022202320242025MRQ
Shares, quarterly12.82814.74414.76414.83119.29421.25123.32823.39724.581
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.010.040.060.1384.6810.657.760.66
Cost of Goods Sold Incl. D&A9.0111.5419.6320.2516.4714.547.47-
Gross Profit-8.99-11.50-19.57-20.1268.22-3.880.28-
Selling, General and Administrative Excl. Other199.26192.27204.32230.61260.03213.22221.6598.36
Research and Development160.22147.14152.28163.62142.72124.16174.7759.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-208.25-203.77-223.89-250.73-191.81-217.10-221.37-102.09
Interest Expense0.000.000.000.000.000.000.00-
Unusual Expense60.5649.47156.1414.7711.2032.992.900.00
Net Income Before Taxes-255.16-274.45-342.99-234.63-183.12-250.22-204.47-129.38
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-255.16-274.45-342.99-234.63-183.12-250.22-204.47-129.38
Net Income From Continuing Operations-255.16-274.45-342.99-234.63-183.12-250.22-204.47-130.52
Net Income-255.16-274.45-342.99-234.63-183.12-250.22-208.05-130.52
EPS (Recurring)-8.71-14.03-17.87-17.87-14.19-18.71-16.71-10.59
EPS (Basic, Before Extraordinaries)-11.50-16.06-26.23-18.70-14.82-20.62-16.88-10.59
EPS (Diluted)-11.50-16.06-26.23-18.70-14.82-20.62-16.88-10.59
EBITDA-199.25-192.24-204.26-230.48-175.34-202.56-213.89-97.71
Non-Operating Income (Expense)13.65-21.2137.0430.8719.89-0.1319.80-27.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense38.9141.8333.1447.0881.9262.2033.2615.73
Price To Sales Ratio15,948.5614,614.512,743.403,745.4410.12176.41--
Gross Margin-59,933.33-31,952.78-32,081.97-15,476.9280.55-36.483.62-
Operating Margin--566,038.89-367,034.43-192,867.69-226.51-2,038.50-2,854.15-15,538.66
Net Margin--762,355.56-562,285.25-180,486.15-216.24-2,349.47-2,682.49-19,866.21
Shares Outstanding24.5821.2514.7412.7012.4812.1412.3312.33
Market Capitalization414.51414.51188.72488.63864.861,878.791,810.41-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.010.010.010.010.01
Cost of Goods Sold Incl. D&A2.052.222.332.402.573.133.445.03
Gross Profit-2.05-2.22-2.33-2.39-2.55-3.13-3.43-5.01
Selling, General and Administrative Excl. Other48.1446.8843.8360.4236.2941.5154.0558.16
Research and Development38.8437.3034.2749.8025.6131.7240.0143.64
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-50.19-49.10-46.16-62.81-38.84-44.63-57.49-63.18
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.260.4017.9142.51-0.832.421.34142.78
Net Income Before Taxes-45.53-44.76-24.15-140.72-38.85-42.68-52.20-191.94
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-45.53-44.76-24.15-140.72-38.85-42.68-52.20-191.94
Net Income From Continuing Operations-45.53-44.76-24.15-140.72-38.85-42.68-52.20-191.94
Net Income-45.53-44.76-24.15-140.72-38.85-42.68-52.20-191.94
EPS (Recurring)-1.87-1.90-0.53-5.22-2.16-2.77-3.47-6.90
EPS (Basic, Before Extraordinaries)-1.86-1.92-1.10-6.62-2.13-2.89-3.54-14.40
EPS (Diluted)-1.86-1.92-1.10-6.62-2.13-2.89-3.54-14.40
EBITDA-48.14-46.87-43.83-60.41-36.28-41.50-54.05-58.15
Non-Operating Income (Expense)4.404.7439.92-35.41-0.834.376.6314.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.514.534.2925.575.235.006.028.08
Price To Sales Ratio15,948.5612,157.9314,155.8918,169.917,235.912,179.502,442.502,796.47
Gross Margin-68,366.67-55,450.00-116,500.00-39,850.00-17,006.67-39,087.50-49,057.14-45,590.91
Operating Margin-----258,960.00-557,937.50-821,228.57-574,354.55
Net Margin-----258,973.33-533,550.00-745,642.86-
Shares Outstanding24.5823.4023.3321.2519.2914.8314.7614.74
Market Capitalization414.51327.84467.54653.89311.99130.90158.86188.72

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments247.22370.53546.22640.15614.79612.62436.05
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets13.729.078.4611.1411.494.934.21
Total Current Assets260.94379.59554.69651.29626.29617.55440.26
Net Property, Plant & Equipment53.6472.94142.32166.26166.64124.0643.70
Total Investments and Advances20.5933.7048.79115.32331.00163.9170.78
Other Assets4.894.624.244.683.482.770.89
Total Assets340.05490.86750.03937.561,127.41908.28555.63
Short Term Debt Incl. Current Port. of LT Debt9.077.976.274.531.173.620.34
Accounts Payable2.895.374.823.923.219.402.84
Other Current Liabilities37.4540.4523.4328.5842.3636.2718.86
Total Current Liabilities49.4153.7934.5237.0346.7449.2822.05
Long Term Debt41.9250.9956.8963.1766.651,061.92546.29
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.523.253.664.1184.2389.6098.41
Total Liabilities91.85108.0395.08104.31197.621,200.81666.74
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity248.20382.82654.95833.25929.79-292.53-111.11
Total Shareholders Equity248.20382.82654.95833.25929.79-292.53-111.11
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity248.20382.82654.95833.25929.79-292.53-111.11
Total Liabilities & Stockholders Equity340.05490.86750.03937.561,127.41908.28555.63
Book Value Per Share11.6825.9751.5866.7876.61-23.73-9.01
Tangible Book Value Per Share11.6825.9751.5866.7876.61-23.73-9.01
Full-Time Employees161300224274190--
Price to Book Ratio2.150.490.701.052.021.84-
Return on Assets-66.06-55.28-27.81-17.74-24.58-27.94-
Return on Equity-86.98-66.10-31.53-20.77-78.53--
Return on Invested Capital-94.60-79.06-32.96-20.43-25.11-26.58-29.99
Quick Ratio5.287.0616.0717.5913.4012.5319.97
Current Ratio5.287.0616.0717.5913.4012.5319.97

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-255.16-274.45-342.99-234.63-183.12-250.22-204.47-129.38
Depreciation9.0111.5419.6318.3816.4714.547.474.38
Other Funds (Non Cash)94.31122.78164.0949.1479.11105.4236.4653.66
Funds from Operations-151.85-140.13-159.27-167.12-87.54-130.26-160.54-71.33
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital12.60-9.89-3.123.42-82.024.01-0.34110.81
Cash from Operating Activities-139.25-150.02-162.39-163.69-169.56-126.25-160.8739.47
Capital Expenditures-0.71-0.78-0.46-2.69-24.28-65.50-51.48-16.05
Net Assets From Acquisitions-41.20-41.20-31.350.000.000.000.000.00
Sale of Fixed Assets and Businesses0.030.290.000.000.000.000.000.00
Purchase or Sale of Investments97.1095.78154.23186.7312.74-56.07-222.03-406.39
Purchase of Investments-177.09-278.90-394.71-476.88-406.32-673.47-908.36-644.84
Sale Or Maturity of Investments274.19374.68548.94663.61419.05617.40686.32238.46
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities55.2254.10122.42184.05-11.54-121.57-273.52-422.43
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock52.5150.411.402.2011.10401.24476.79351.16
Repurchase of Common Pref Stock0.000.000.000.000.000.00-16.05-0.18
Sale of Common Pref Stock52.5150.411.402.2011.10401.24492.84351.34
Proceedsfrom Stock Options52.5850.371.251.891.52391.80492.47351.34
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-0.00-0.08-0.46-0.460.000.000.00
Other Financing Activities Uses-0.00-0.00-0.08-0.46-0.460.000.000.00
Cash from Financing Activities52.5150.411.331.7410.63401.24476.79351.16
Net Change in Cash-31.52-45.52-38.6422.10-170.46153.4242.40-31.80
Free Cash Flow-139.97-150.80-162.86-166.38-193.83-191.75-212.3523.43
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments177.11204.10254.02247.22319.62276.79
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets9.119.4413.2813.728.585.42
Total Current Assets186.21213.54267.30260.94328.20282.21
Net Property, Plant & Equipment44.2647.2950.5553.6456.6360.07
Total Investments and Advances37.4744.4827.5420.5920.5940.64
Other Assets5.915.845.234.892.542.53
Total Assets273.85311.15350.63340.05407.96385.45
Short Term Debt Incl. Current Port. of LT Debt9.979.669.369.078.790.00
Accounts Payable4.043.885.472.892.573.38
Other Current Liabilities32.2726.3222.1137.4520.5233.52
Total Current Liabilities46.2739.8736.9549.4131.8836.90
Long Term Debt34.3136.9339.4941.9244.2846.60
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.550.540.530.522.683.03
Total Liabilities81.1377.3476.9691.8578.8486.53
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity192.72233.81273.67248.20329.12298.92
Total Shareholders Equity192.72233.81273.67248.20329.12298.92
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity192.72233.81273.67248.20329.12298.92
Total Liabilities & Stockholders Equity273.85311.15350.63340.05407.96385.45
Book Value Per Share7.849.9911.7311.6817.0620.16
Tangible Book Value Per Share7.849.9911.7311.6817.0620.16
Full-Time Employees---161--
Price to Book Ratio2.151.201.721.800.810.39
Return on Assets-74.85-71.34-63.15-66.06-63.41-63.76
Return on Equity-97.79-93.28-80.76-86.98-75.75-76.59
Return on Invested Capital-20.05-16.53-7.71-48.50-10.40-12.35
Quick Ratio4.025.367.235.2810.307.65
Current Ratio4.025.367.235.2810.307.65

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-45.53-44.76-24.15-140.72-38.85-42.68
Depreciation2.052.222.332.402.573.13
Other Funds (Non Cash)2.292.22-15.61105.407.845.97
Funds from Operations-41.19-40.31-37.43-32.92-28.44-33.58
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital6.626.39-1.080.67-0.14-0.88
Cash from Operating Activities-34.57-33.92-38.51-32.25-28.58-34.46
Capital Expenditures-0.07-0.26-0.09-0.30-0.06-0.17
Net Assets From Acquisitions0.000.000.00-41.200.000.00
Sale of Fixed Assets and Businesses0.000.010.000.020.260.00
Purchase or Sale of Investments53.6615.8717.4710.113.1512.81
Purchase of Investments-43.58-53.52-37.18-42.80-70.99-80.70
Sale Or Maturity of Investments97.2469.3954.6552.9174.1493.52
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities53.5915.6217.38-31.363.3512.65
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.040.5251.720.2250.000.18
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.040.5251.720.2250.000.18
Proceedsfrom Stock Options0.000.5251.700.3650.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.000.00-0.00
Other Financing Activities Uses0.000.000.00-0.000.000.00
Cash from Financing Activities0.040.5251.720.2250.000.18
Net Change in Cash19.07-17.7830.59-63.3924.77-21.63
Free Cash Flow-34.63-34.18-38.60-32.55-28.64-34.63

Revenue breakdown

Pharmaceutical Preparations2024: 61.00K 2025: 36.00K
United States2024: 61.00K 2025: 36.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.86%1.4M8.9M150.70K
2026-10-1515.78%1.4M8.9M152.01K
2026-09-3014.26%1.3M8.9M152.26K
2026-09-1513.41%1.2M8.9M181.30K
2026-08-3112.74%1.1M8.9M186.91K
2026-08-1412.98%1.2M8.9M181.13K
2026-07-3117.01%1.2M7.2M160.05K
2026-07-1517.05%1.2M7.2M147.72K
2026-06-3017.96%1.2M6.8M134.35K
2026-06-1519.53%1.3M6.7M91.46K
2026-05-2917.42%1.4M7.8M86.20K
2026-05-1517.25%1.3M7.8M93.54K
2026-04-3016.53%1.3M8.1M100.12K
2026-04-1512.93%1.2M9.6M102.88K
2026-03-3114.34%1.1M7.9M102.95K
2026-03-1311.84%0.9M7.9M114.17K
2026-02-2711.28%0.8M7.2M106.46K
2026-02-138.19%0.6M7.2M93.30K
2026-01-307.24%0.5M7.2M82.29K
2026-01-155.66%0.4M7.2M71.94K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call3.0011.5016.100.0020.0710.000.000.992-0.0180.001
call4.0010.5015.100.0015.1460.000.000.991-0.0180.001
call5.009.5014.000.0012.1190.000.000.989-0.0180.001
call6.008.5013.300.0011.1620.000.000.987-0.0180.001
call7.007.5012.200.009.4350.000.000.922-0.1290.004
call8.006.5011.202.508.26883.000.000.903-0.1410.005
call9.005.5010.200.007.2870.000.000.887-0.1380.005
call10.004.509.200.006.4420.000.000.870-0.1340.006
call11.003.508.200.005.6920.000.000.849-0.3340.006
call12.002.507.200.005.0140.000.000.822-0.3320.007
call13.001.506.300.004.5140.000.000.792-0.3260.008
call14.000.805.502.604.15210.000.000.760-0.3160.008
call15.000.205.000.004.1130.000.000.725-0.3020.009
call16.000.305.000.004.5580.000.000.681-0.2760.009
call17.000.004.900.004.8350.000.000.641-0.2660.010
call18.000.004.900.005.1722.000.000.620-0.2830.010
call19.000.004.900.005.4952.000.000.613-0.3120.010
call20.000.004.900.004.6690.000.000.552-0.2750.010
call21.000.004.900.005.7740.000.000.591-0.3380.010
call22.000.004.900.005.7930.000.000.582-0.3450.011
call23.000.004.900.006.1250.000.000.574-0.3600.011
call24.000.004.900.004.6820.000.000.451-0.2740.010
call25.000.004.900.006.8090.000.000.563-0.3990.010
call26.000.004.900.006.7860.000.000.555-0.4050.011
call27.000.004.900.007.1440.000.000.553-0.4200.010
call28.000.004.900.006.9930.000.000.545-0.4160.011
call29.000.004.900.005.9080.000.000.449-0.3470.010
call30.000.004.900.007.2070.000.000.536-0.4340.011
put3.000.000.050.005.2830.000.00-0.008-0.0160.001
put4.000.004.900.009.2450.000.00-0.042-0.1230.002
put5.000.004.900.007.8550.000.00-0.053-0.1260.003
put6.000.002.250.053.40610.000.00-0.013-0.0170.001
put7.000.000.850.005.6030.000.00-0.079-0.1160.004
put8.000.004.900.005.5200.000.00-0.094-0.1380.005
put9.000.004.901.204.8481,0000.00-0.109-0.1350.005
put10.000.001.000.003.9870.000.00-0.132-0.1190.006
put11.000.004.900.209.5978.000.00-0.151-0.3320.006
put12.000.004.900.008.5670.000.00-0.178-0.3310.007
put13.000.004.900.007.6540.000.00-0.201-0.3210.008
put14.000.004.900.006.8310.000.00-0.240-0.3140.008
put15.000.004.901.456.15210.000.00-0.265-0.3030.009
put16.000.004.900.005.3790.000.00-0.319-0.2740.009
put17.000.004.900.904.7090.001.00-0.359-0.2640.010
put18.000.305.000.004.0590.000.00-0.380-0.2810.010
put19.000.004.900.003.4980.000.00-0.387-0.3040.010
put20.000.705.500.003.3100.000.00-0.399-0.3270.010
put21.001.806.500.003.5640.000.00-0.461-0.2880.010
put22.002.757.500.003.7960.000.00-0.417-0.3580.010
put23.003.808.500.004.0090.000.00-0.424-0.3720.010
put24.004.609.500.004.2060.000.00-0.431-0.3840.010
put25.005.6010.500.004.3890.000.00-0.437-0.3960.010
put26.006.6011.300.004.3620.000.00-0.442-0.4070.010
put27.007.6012.500.004.7220.000.00-0.447-0.4170.010
put28.008.7013.100.004.4700.000.00-0.452-0.4260.010
put29.009.7014.500.005.0180.000.00-0.456-0.4350.010
put30.0010.7015.500.005.1550.000.00-0.459-0.4440.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-048-KCurrent report2026-11-03SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-103Initial statement of beneficial ownership of securities2026-08-31SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-108-KCurrent report2026-09-10SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-21EFFECTEffectiveness filing by commission orderSEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-17CORRESPSEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-16UPLOADUpload SubmissionSEC
2026-07-13S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1150.00M200
2026-10003.64K1
2026-09006.35K1
2026-0800204.68K7
2026-07002742
2026-060024.99K1
2026-050015.58K4
2026-040000
2026-0325.00M200
2026-0200264.28K7
2026-010000
2025-120074.18K2
2025-110014.25K4

Institutional holders

Manager% owned
ARCH Venture Management, LLC13.92%
GSK plc6.17%
VANGUARD CAPITAL MANAGEMENT LLC3.37%
Orland Properties Ltd3.23%
BlackRock, Inc.3.10%
Decheng Capital LLC2.97%
Almitas Capital LLC2.49%
Foresite Capital Management V, LLC2.04%
MILLENNIUM MANAGEMENT LLC1.57%
Opaleye Management Inc.1.47%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.59%
iShares Russell 2000 ETF0.97%
VANGUARD EXTENDED MARKET INDEX FUND0.70%
Fidelity Small Cap Index Fund0.42%
iShares Russell 2000 Value ETF0.38%
Schwab U.S. Small-Cap ETF0.27%
iShares Biotechnology ETF0.23%
VANGUARD RUSSELL 2000 INDEX FUND0.22%
Fidelity Extended Market Index Fund0.21%
iShares Micro-Cap ETF0.14%

OakChart. LYEL. Cached 15 minutes.